LT2861602T - 7-metil-2-[4-metil-6-[4-(trifluormetil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-onas - Google Patents

7-metil-2-[4-metil-6-[4-(trifluormetil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-onas

Info

Publication number
LT2861602T
LT2861602T LTEP13725438.9T LT13725438T LT2861602T LT 2861602 T LT2861602 T LT 2861602T LT 13725438 T LT13725438 T LT 13725438T LT 2861602 T LT2861602 T LT 2861602T
Authority
LT
Lithuania
Prior art keywords
methyl
diazaspiro
nonan
pyrimidin
trifluoromethyl
Prior art date
Application number
LTEP13725438.9T
Other languages
English (en)
Lithuanian (lt)
Inventor
Gerard M P GIBLIN
David T Macpherson
David R Witty
Steven J STANWAY
Original Assignee
Convergence Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convergence Pharmaceuticals Limited filed Critical Convergence Pharmaceuticals Limited
Publication of LT2861602T publication Critical patent/LT2861602T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LTEP13725438.9T 2012-05-22 2013-05-22 7-metil-2-[4-metil-6-[4-(trifluormetil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-onas LT2861602T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261650325P 2012-05-22 2012-05-22
GB201209015A GB201209015D0 (en) 2012-05-22 2012-05-22 Novel compounds
US201361773710P 2013-03-06 2013-03-06
PCT/GB2013/051335 WO2013175205A1 (en) 2012-05-22 2013-05-22 Novel Compounds

Publications (1)

Publication Number Publication Date
LT2861602T true LT2861602T (lt) 2016-11-10

Family

ID=46546493

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP13725438.9T LT2861602T (lt) 2012-05-22 2013-05-22 7-metil-2-[4-metil-6-[4-(trifluormetil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-onas
LTEP16177700.8T LT3106464T (lt) 2012-05-22 2013-05-22 Naujieji junginiai

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP16177700.8T LT3106464T (lt) 2012-05-22 2013-05-22 Naujieji junginiai

Country Status (27)

Country Link
US (7) US9309254B2 (enExample)
EP (3) EP2861602B1 (enExample)
JP (3) JP2015517562A (enExample)
KR (2) KR102161101B1 (enExample)
CN (2) CN107344942B (enExample)
AU (3) AU2013265001B2 (enExample)
BR (1) BR112014029280B1 (enExample)
CA (1) CA2873956C (enExample)
CY (2) CY1118274T1 (enExample)
DK (2) DK2861602T3 (enExample)
EA (1) EA025579B1 (enExample)
ES (3) ES2602308T3 (enExample)
GB (1) GB201209015D0 (enExample)
HR (2) HRP20161349T1 (enExample)
HU (2) HUE049445T2 (enExample)
IL (4) IL235805A (enExample)
IN (1) IN2014MN02393A (enExample)
LT (2) LT2861602T (enExample)
MX (1) MX355303B (enExample)
PL (2) PL2861602T3 (enExample)
PT (2) PT3106464T (enExample)
RS (2) RS55415B1 (enExample)
SG (2) SG11201407755UA (enExample)
SI (2) SI2861602T1 (enExample)
SM (2) SMT202000210T1 (enExample)
WO (2) WO2013175206A1 (enExample)
ZA (1) ZA201408253B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
MX2020003741A (es) * 2017-09-28 2021-01-08 Biogen Inc Sales novedosas.
CA3077088A1 (en) * 2017-10-10 2019-04-18 Biogen Inc. Process for preparing spiro derivatives
WO2022133097A1 (en) * 2020-12-17 2022-06-23 Biogen Ma Inc. Synthesis of compounds that modulate use-dependent voltage-gated sodium channels

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL165829A0 (en) * 2002-07-05 2006-01-15 Targacept Inc N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
GB0520578D0 (en) * 2005-10-10 2005-11-16 Glaxo Group Ltd Novel compounds
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
US7855218B2 (en) 2005-10-10 2010-12-21 Convergence Pharmaceuticals Limited Compounds
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
US8143306B2 (en) 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
US7683083B2 (en) * 2005-10-12 2010-03-23 Vertex Pharmaceuticals Incorporated Biphenyl derivatives as modulators of voltage gated ion channels
US7998959B2 (en) * 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
CL2007002953A1 (es) 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
MX2009003874A (es) * 2006-10-12 2009-04-22 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
HRP20150491T1 (hr) 2009-09-14 2015-08-14 Convergence Pharmaceuticals Limited PROCES PRIPREME DERIVATA α-KARBOKSAMIDA
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
HK1206511A1 (en) * 2012-03-21 2016-01-08 Interdigital Patent Holdings, Inc. Sponsoring of a mobile station session by another mobile station in a wireless network
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
GB201209670D0 (en) 2012-05-31 2012-07-18 Convergence Pharmaceuticals Novel compounds

Also Published As

Publication number Publication date
US20160184306A1 (en) 2016-06-30
SMT201600421B (it) 2017-01-10
US10485801B2 (en) 2019-11-26
EP3106464B1 (en) 2020-01-08
ES2782088T3 (es) 2020-09-10
ZA201408253B (en) 2015-12-23
IL280595A (en) 2021-03-25
CY1123044T1 (el) 2021-10-29
BR112014029280B1 (pt) 2022-10-04
RS60368B1 (sr) 2020-07-31
KR20200113027A (ko) 2020-10-05
IL235805A0 (en) 2015-02-01
AU2018201653A1 (en) 2018-03-29
AU2017201421A1 (en) 2017-03-23
MX2014014274A (es) 2015-06-17
CY1118274T1 (el) 2017-06-28
WO2013175205A1 (en) 2013-11-28
PL2861602T3 (pl) 2017-05-31
US9737536B2 (en) 2017-08-22
US10010551B2 (en) 2018-07-03
HRP20161349T1 (hr) 2017-01-27
US20170304303A1 (en) 2017-10-26
EP3106464A1 (en) 2016-12-21
JP2015517561A (ja) 2015-06-22
US9376445B2 (en) 2016-06-28
US9309254B2 (en) 2016-04-12
CN104640867B (zh) 2017-07-21
SI3106464T1 (sl) 2020-12-31
CA2873956A1 (en) 2013-11-28
US20200289508A1 (en) 2020-09-17
ES2602193T3 (es) 2017-02-20
HRP20200580T1 (hr) 2020-10-02
IL271330A (en) 2020-01-30
LT3106464T (lt) 2020-04-10
CN104640867A (zh) 2015-05-20
HUE049445T2 (hu) 2020-09-28
SI2861602T1 (sl) 2017-03-31
ES2602308T3 (es) 2017-02-20
SG11201407755UA (en) 2014-12-30
AU2018201653B2 (en) 2019-05-02
CA2873956C (en) 2021-03-23
BR112014029280A2 (pt) 2017-06-27
IL235805A (en) 2017-05-29
IL252033A0 (en) 2017-06-29
MX355303B (es) 2018-04-12
JP2017206534A (ja) 2017-11-24
SG10201703527WA (en) 2017-06-29
IL271330B (en) 2021-02-28
AU2017201421B2 (en) 2017-12-07
EP2861602A1 (en) 2015-04-22
EP2861594B1 (en) 2016-08-24
JP6378404B2 (ja) 2018-08-22
SMT202000210T1 (it) 2020-05-08
DK3106464T3 (da) 2020-03-23
KR20150023401A (ko) 2015-03-05
PT2861602T (pt) 2016-11-14
US20150166551A1 (en) 2015-06-18
HUE031664T2 (en) 2017-07-28
CN107344942A (zh) 2017-11-14
US20150119404A1 (en) 2015-04-30
US20180360833A1 (en) 2018-12-20
GB201209015D0 (en) 2012-07-04
AU2013265001A1 (en) 2014-12-18
PT3106464T (pt) 2020-04-03
AU2013265001B2 (en) 2016-12-01
DK2861602T3 (en) 2016-11-28
IL252033B (en) 2019-12-31
HK1209423A1 (en) 2016-04-01
IN2014MN02393A (enExample) 2015-08-21
CN107344942B (zh) 2020-09-25
JP2015517562A (ja) 2015-06-22
WO2013175206A1 (en) 2013-11-28
EA025579B1 (ru) 2017-01-30
US20160263115A1 (en) 2016-09-15
EP2861594A1 (en) 2015-04-22
EA201492169A1 (ru) 2015-04-30
PL3106464T3 (pl) 2020-11-16
RS55415B1 (sr) 2017-04-28
JP6169687B2 (ja) 2017-07-26
KR102161101B1 (ko) 2020-10-20
EP2861602B1 (en) 2016-08-10

Similar Documents

Publication Publication Date Title
AP2012006192A0 (en) PyrroloÄ2,3-DÜ pyrimidine compounds.
IL236898A0 (en) 2, 3- benzodiazepines
GB201304967D0 (en) .
DK2364624T3 (da) Kaffedriksystem, kaffebrygningsapparat
GB201204183D0 (en) .
AP2012006242A0 (en) Anticoagulant antidotes.
PT2861602T (pt) 7-metil-2-[4-metil-6-[4-(trifluorometil)-fenil]pirimidin-2-il]-1,7-diazaspiro[4.4]nonan-6-ona
EP2573067A4 (en) AROMATIC BUTANE-2-OL COMPOUNDS AND MANUFACTURING METHOD AND USES THEREOF
刘金强 et al. 全自动立式压滤机在黄金选矿厂中的应用实践
李晶莹 et al. 电子废弃物中生物冶金技术的研究进展
Heilen des Antigonos von Nikaia
Grewal When Nice Guys Finish First
李威 et al. 矿山技术经济指标动态优化研究
Von Hellermann Multi-sited ethnography
李石桥 et al. 甘肃阳山金矿床充水因素分析
国兴伟 et al. 沂南金矿矽卡岩型多金属矿床成矿规律及深部找矿预测
田宏伟 et al. 祁雨沟隐爆角砾岩型金矿床资源评价
刘子龙 et al. 影响生物氧化提金工艺的主要因素与措施
谢覃江 et al. 云南马鹿塘金矿床地质特征及成因探讨
Agerstam The Courtyard
Bargiel Intermezzo für Orchester, op. 46. Partitur.
王宝胜 et al. 三山岛金矿新立分矿选矿厂磨矿分级系统改造与应用
Marco Aguilar Six Houses, Paired 2-2
朱松亚 Photo
许洪元 吉林石井金银矿床地质特征及成因探讨